{"filings":[{"id":2033516,"accession_number":"0001193125-26-331522","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2026-08-04T11:09:08+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Therapeutics Q2 net loss $122.7M; first patient dosed in BEAM-302 pivotal trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $122.7M ($1.18 per share) vs $102.1M loss in Q2 2025; R&D expenses $95.1M.","First patient dosed in global pivotal cohort of BEAM-302 for AATD; updated data at ERS Congress Sept 2026.","Dosing complete for all patients in BEACON trial of risto-cel for SCD; BLA submission expected as early as year-end 2026.","FDA cleared IND for BEAM-304 in PKU; clinical start-up activities underway.","Cash $1.2B as of June 30, 2026; with $200M from Sixth Street, runway into mid-2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":918077,"accession_number":"0001193125-26-261693","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2026-06-08T20:05:15+00:00","items":["5.07"],"status":"ready","headline":"Beam Therapeutics 2026 annual meeting results: all director nominees and proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["John Evans, John Maraganore, and Christi Shaw elected as Class III directors with 71.7M, 64.8M, and 65.7M votes for respectively.","Ratification of Deloitte as auditor for FY2026 passed with 85.8M votes for, 165.7K against.","Advisory say-on-pay resolution approved with 71.5M for, 985.1K against.","Broker non-votes totaled approximately 13.4M shares for director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95145,"accession_number":"0001193125-26-210299","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Therapeutics Reports Q1 2026 Results; BEAM-302 Pivotal Cohort and Risto-cel BLA on Track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["BEAM-302 Phase 1/2 data showed single-dose safety and efficacy; 60 mg selected as optimal dose; global pivotal cohort to start H2 2026.","Risto-cel (BEAM-101) Phase 1/2 data published in NEJM; BLA submission expected as early as year-end 2026 for sickle cell disease.","Cash, cash equivalents and marketable securities were $1.2 billion as of March 31, 2026; cash runway into mid-2029.","Net loss of $94.3 million ($0.91 per share) for Q1 2026, compared to net loss of $108.3 million ($1.23 per share) in Q1 2025.","IND filing for BEAM-304 in PKU and initial data for BEAM-301 in GSDIa expected in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":31738000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108006,"accession_number":"0001193125-26-093914","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Beam terminates license pact with Bio Palette; Kobe University standby license activated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mutual termination of License Agreement with Bio Palette effective March 2, 2026 due to Bio Palette's planned dissolution.","Standby License Agreement with Kobe University activated, granting Beam exclusive license to base editing patents previously covered.","No future payments due between Beam and Bio Palette under the Termination Agreement or License Agreement.","Beam retains rights to exploit base editing technology for human disease worldwide, minus microbiome field in Asia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108005,"accession_number":"0001193125-26-065191","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"Beam Q4 net income $244.3M (full-year loss $80.0M); new PKU program; $500M Sixth Street credit facility","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net income $244.3M ($2.33 diluted EPS); full-year net loss $80.0M ($0.81 per share).","New liver-targeted program BEAM-304 for PKU; IND filing expected in 2026; targets two most prevalent PAH mutations.","$500M senior secured credit facility with Sixth Street; $100M funded at close; additional draws tied to risto-cel milestones.","Cash, cash equivalents and marketable securities $1.25B as of Dec 31, 2025; runway into mid-2029 with Sixth Street capital.","Risto-cel BLA submission expected as early as year-end 2026; BEAM-302 FDA alignment on accelerated approval path."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":139743000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108004,"accession_number":"0001193125-26-048684","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Beam Therapeutics secures standby direct license to Kobe University patents for base editing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement dated Feb 9, 2026 among Beam, Bio Palette, and Kobe University ensures backup patent access.","If Kobe-Bio Palette license terminates (barring Beam-caused breach), Kobe grants Beam an exclusive direct license.","Beam will pay Kobe the same amounts it would have paid Bio Palette under the original sublicense.","Beam assumes prosecution and maintenance costs for Kobe patents after the effective time.","Standby license covers the same scope as Beam's current sublicense from Bio Palette."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108003,"accession_number":"0001193125-26-039365","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Carole Ho resigns from Beam Therapeutics board effective Feb 27, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carole Ho notified resignation on Jan 31, 2026, effective Feb 27, 2026.","Resignation not due to any disagreement with Beam on operations, policies, or practices.","No successor or replacement director announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108002,"accession_number":"0001193125-26-009722","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Beam reports $1.25B cash, FDA alignment on BEAM-302 accelerated path; risto-cel BLA expected year-end 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Estimated $1.25B cash, cash equivalents and marketable securities as of Dec 31, 2025; operating runway extended into 2029.","FDA alignment on potential accelerated approval for BEAM-302 based on AAT biomarkers over 12 months; ~50 additional patients to be enrolled.","BLA submission for risto-cel (formerly BEAM-101) expected as early as year-end 2026; BEACON trial fully enrolled, manufacturing done December 2025.","Updated BEAM-302 Phase 1/2 data and pivotal plan expected by end of Q1 2026; new liver-targeted program to be announced H1 2026.","Initial BEAM-301 clinical data expected in 2026; BEAM-103 Phase 1 healthy volunteer trial to complete dosing in H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124417,"accession_number":"0001193125-25-316043","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["2.01"],"status":"ready","headline":"Beam Therapeutics nets $255.1M cash from sale of Orbital stake in BMS acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Beam received $255.1M in closing cash plus up to ~$26.3M from escrow for its 75M shares (17% fully diluted) of Orbital.","Bristol-Myers Squibb completed acquisition of Orbital on December 8, 2025, triggering the payout.","Beam to update cash runway guidance at the 2026 J.P. Morgan Healthcare Conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124416,"accession_number":"0001193125-25-263536","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Q3 net loss $112.7M; cash $1.1B; BEAM-302 expands; Orbital acquisition by BMS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $112.7M ($1.10 per share) in Q3 2025 vs $96.7M ($1.17 per share) in Q3 2024.","Cash, cash equivalents and marketable securities $1.1B as of Sep 30, 2025, up from $850.7M at Dec 31, 2024; runway into 2028.","BEAM-302 expanded: multi-dose cohort (60 mg x2, 8 wks apart) in Part A; first patient dosed in Part B (liver disease). Data in early 2026.","BEAM-101 updated data accepted for ASH Dec 2025; FDA granted RMAT designation in Aug 2025.","First subject dosed with BEAM-103 (ESCAPE mAb) in Phase 1 HV trial; BMS to acquire Orbital for $1.5B; Beam holds ~17% stake."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":25634000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141086,"accession_number":"0000950170-25-102389","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Q2 net loss $102.3M; cash $1.2B; BEAM-302 17 patients dosed; BEAM-101 enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $102.3M ($1.00/share) vs $91.1M loss ($1.11/share) in Q2 2024; R&D expense rose to $101.8M.","Cash, cash equivalents and marketable securities $1.2B as of June 30, 2025; runway into 2028.","BEAM-302 Phase 1/2: 17 patients dosed; expanded dose exploration underway; Part B enrollment initiated; data expected early 2026.","BEAM-101 BEACON trial: 30 SCD patients dosed (adults + first adolescent); updated data expected by end of 2025.","FDA granted orphan drug designation for BEAM-101 and BEAM-302, and RMAT designation for BEAM-302."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":15936000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141085,"accession_number":"0000950170-25-093906","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Beam Therapeutics acquires early-stage life sciences company for 403k shares plus up to $89M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront consideration: 403,128 shares of BEAM common stock (~$6.86M based on $17.01 close).","Earnout: up to $89M in development, clinical, and commercial milestones, payable in cash or stock at Beam's discretion.","If milestones paid in stock, maximum issuable shares ~5.23M based on $17.01 closing price.","Shares issued as unregistered securities under Section 4(a)(2) exemption.","Target is an early-stage life sciences company; name not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158889,"accession_number":"0000950170-25-083043","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Beam Therapeutics shareholders elect directors, ratify Deloitte, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected Mark Fishman (61.9M for, 10.3M against), Carole Ho (71.7M for), and Kathleen Walsh (71.9M for) as Class II directors.","Ratified Deloitte & Touche as independent auditor for FY2025 with 84.3M for, 154K against, 63.6K abstentions.","Advisory vote on named executive officer compensation approved: 71.7M for, 562.9K against, 33.9K abstentions.","All proposals passed; broker non-votes were 12.2M on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158888,"accession_number":"0000950170-25-063955","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Q1 net loss $109.3M; cash $1.2B after $500M financing; clinical milestones hit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $109.3M ($1.24/share) vs $98.7M ($1.21/share) Q1 2024; R&D spend $98.8M.","Cash $1.2B including $500M financing; runway into 2028.","First patient dosed for BEAM-301 in GSDIa; IND cleared for BEAM-302 in AATD.","BEAM-101 updated data accepted at EHA June 2025; aim to dose 30 SCD patients by mid-2025.","BEAM-302 fourth cohort dosing started; further data expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":7470000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177291,"accession_number":"0001193125-25-051072","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Beam prices $500M underwritten offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten offering of 16,151,686 shares at $28.48 per share and pre-funded warrants for 1,404,988 shares at $28.47 each.","Gross proceeds ~$500.0M; net proceeds after discounts and expenses ~$469.7M.","Use of proceeds: platform technology, R&D for BEAM-101, BEAM-302 pivotal trial, ESCAPE conditioning trial, general corporate.","Closing expected March 11, 2025; J.P. Morgan, Jefferies, Cantor, Citigroup, Wells Fargo as joint bookrunners.","Pre-funded warrants exercisable immediately at $0.01 per share, with cashless exercise and beneficial ownership limitation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177290,"accession_number":"0001193125-25-050334","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Beam reports positive initial Phase 1/2 data for BEAM-302 in AATD; total AAT exceeds protective threshold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BEAM-302 well tolerated at all doses; no serious AEs or dose-limiting toxicities observed.","Single 60 mg dose achieved mean total AAT of 12.4 µM at Day 28, exceeding 11 µM protective threshold.","Mutant Z-AAT reduced up to 78% from baseline at 60 mg dose level.","First clinical evidence of precise genetic correction of a disease-causing mutation via base editing.","Dose escalation to continue; further data expected at medical conference in H2 2025; Part B dosing planned H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177289,"accession_number":"0000950170-25-026070","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Therapeutics reports Q4 net loss of $90.4M; cash $850.7M, clinical milestones reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss per share $1.09 in Q4 2024 vs net income of $1.77 in Q4 2023; full-year net loss $4.58 per share vs $1.72 in 2023.","Cash, equivalents and marketable securities $850.7M at Dec 31, 2024, expected to fund operations into 2027.","Adult enrollment target achieved in BEACON trial of BEAM-101; updated data and 30 patients dosed expected by mid-2025.","Initial data from BEAM-302 Phase 1/2 in alpha-1 antitrypsin deficiency expected in H1 2025; BEAM-301 dosing to start early 2025.","Appointed Sravan Emany as CFO; Chirfi Guindo to board; IND-enabling studies for ESCAPE conditioning ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":63518000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177288,"accession_number":"0000950170-25-004558","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Beam Therapeutics: $850.7M cash, pipeline progress, 2025 catalysts detailed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary cash, equivalents and marketable securities of $850.7M as of Dec 31, 2024; runway now into 2027 including BEAM-101 commercial readiness.","More than 40 adult SCD patients enrolled in BEACON trial; Beam expects to dose 30 patients and present updated data by mid-2025.","Initial Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency expected in first half 2025.","BEAM-301 Phase 1/2 trial in GSD1a: first site active, dosing to commence in early 2025.","ESCAPE nongenotoxic conditioning IND-enabling studies underway; BEAM-103 healthy volunteer study expected by end of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194051,"accession_number":"0001193125-24-272860","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Beam reports BEAM-101 Phase 1/2 data: all 7 patients achieved >60% HbF, resolved anemia; ESCAPE proof-of-concept in NHPs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Seven patients dosed with BEAM-101 achieved HbF >60%, HbS <40%, and resolution of anemia; no VOCs post-engraftment.","Mean neutrophil engraftment 17.1 days, platelet 19.1 days; one death from busulfan-related respiratory failure deemed unrelated.","ESCAPE antibody conditioning in NHPs enabled long-term engraftment of base-edited HSCs with >80% HbF-containing cells.","BEAM-103 mAb dosing was well tolerated without transfusions or supportive care; minor declines in neutrophils/platelets.","BEAM-302 initial clinical data from multiple cohorts now expected in first half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194050,"accession_number":"0001193125-24-271965","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Beam Therapeutics appoints Sravan Emany as CFO effective Dec 19, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sravan Emany previously CFO/COO of Ironwood Pharmaceuticals; also held roles at Integra, Bank of America, Goldman Sachs.","Annual base salary of $575,000; sign-on bonus of $325,000; target annual incentive bonus of 50% of salary.","Granted incentive stock option for 160,000 shares and restricted stock units for 80,000 shares, both vesting over four years.","Under the offer letter, severance includes 12 months base salary and COBRA premiums if terminated without cause.","Appointment effective December 19, 2024; Emany will serve as principal financial officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194049,"accession_number":"0001193125-24-270314","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-12-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Beam Therapeutics appoints Chirfi Guindo to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chirfi Guindo, chief marketing officer of Human Health at Merck, appointed to Beam's board.","Board expanded from seven to eight members; Guindo elected as Class I director effective Dec. 2, 2024.","Guindo brings 25+ years at Merck and Biogen, expertise in global strategy and commercial operations.","He will serve on the Compensation Committee of the board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194048,"accession_number":"0000950170-24-121099","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Beam reports initial BEAM-101 clinical data: engraftment, HbF >60%, one death from busulfan conditioning","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["BEAM-101 (sickle cell disease): 4 patients engrafted, median 17 days neutrophil, 20 days platelet; HbF >60% by month 1.","BEAM-101: One death from respiratory failure attributed to busulfan conditioning, not BEAM-101; DSMC and FDA reviewed.","BEAM-201 (T-ALL/T-LL): 2 of 3 patients achieved CRi/CR at doses <200 million cells; both eligible for stem cell transplant.","ESCAPE NHP data: CD117 mAb conditioning well tolerated; HbF reached ~85% F-cells by 35 weeks in both animals.","Initial data from BEACON trial also showed no VOCs post-treatment and normalization of hemolysis markers in all 4 evaluable patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194047,"accession_number":"0000950170-24-121088","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Beam Therapeutics discusses Q3 results and ASH abstracts on investor call","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Investor presentation covered Q3 financial results, but no specific figures provided in filing.","Presented preclinical and clinical data from ASH abstracts, including ESCAPE and BEAM-101.","Company reiterated sickle cell disease strategy and provided business update."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":33451000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194046,"accession_number":"0000950170-24-121069","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Therapeutics Q3 net loss $96.7M; cash $925.8M; BEAM-101 enrollment at 35 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $96.7M ($1.17/share) vs $96.1M ($1.22) Q3 2023; R&D $94.3M, G&A $26.5M.","Cash, equivalents, and marketable securities $925.8M as of Sep 30, 2024; runway into 2027.","BEACON trial of BEAM-101: 35 patients enrolled, 8 dosed in sickle cell disease; ASH data Dec 2024.","First cohort dosing complete for BEAM-302 in alpha-1 antitrypsin deficiency; initial data expected 2025.","ESCAPE platform (BEAM-103/104) nominated for development in SCD and beta-thalassemia."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":33451000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210380,"accession_number":"0000950170-24-091201","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Therapeutics Q2 net loss $91.1M; cash $1.0B; BEAM-101 enrollment tops 20, six dosed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss widened to $91.1M ($1.11/shr) from $82.8M ($1.08/shr) in Q2 2023.","Cash, cash equivalents and marketable securities $1.0B at June 30 vs $1.2B at Dec 31, 2023.","BEAM-101 Phase 1/2 BEACON trial: >20 patients enrolled, 6 dosed; initial data submitted for ASH.","FDA cleared IND for BEAM-301 (GSDIa); patient dosing expected in early 2025.","First patient dosed in BEAM-302 Phase 1/2 trial (AATD); initial clinical data expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":19182000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210379,"accession_number":"0001193125-24-178824","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Beam Therapeutics CFO Terry-Ann Burrell resigns; CEO John Evans named interim principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Terry-Ann Burrell resigns effective Aug 9, 2024 to join JPMorgan as vice chairman of investment banking.","CEO John Evans appointed Principal Financial and Accounting Officer upon her departure, continuing as CEO.","Company initiates search for a permanent CFO successor.","Burrell had served as CFO for 5 years, overseeing IPO and capital raising efforts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228700,"accession_number":"0000950170-24-071345","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Beam Therapeutics shareholders elect Graham Cooper as Class I director, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Graham Cooper elected to board with 49.5M for, 6.5M against, 1.8M abstain, 8.4M broker non-votes.","Deloitte & Touche ratified as auditor for FY2024: 66.0M for, 176k against, 42k abstain.","Advisory vote on executive compensation passed: 56.5M for, 1.3M against, 45k abstain, 8.4M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228699,"accession_number":"0000950170-24-053928","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Therapeutics Q1 net loss $98.7M; BEAM-101 expansion cohort opened, cash $1.1B into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $98.7M ($1.21 per share) vs $96.5M ($1.33 per share) in Q1 2023.","Cash, cash equivalents and marketable securities $1.1B as of March 31, 2024; runway into 2027.","R&D expenses $84.8M, G&A expenses $26.7M for Q1 2024.","BEAM-101 BEACON trial sentinel cohort dosing completed; expansion cohort initiated with up to 45 patients.","BEAM-302 CTA cleared in UK for Phase 1/2 in AATD; BEAM-301 IND submission on track for H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":7410000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247335,"accession_number":"0000950170-24-020608","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Therapeutics Q4 net income $142.8M; cash $1.2B, runway to 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net income $142.8M ($1.77 basic EPS) vs net loss $38.3M in Q4 2022; full-year net loss $132.5M vs $289.1M loss in 2022.","Cash, equivalents and marketable securities $1.2B at Dec 31, 2023, expected to fund operations into 2027.","BEAM-101 in SCD: sentinel cohort dosing and expansion cohort initiation H1 2024; initial clinical data expected H2 2024.","BEAM-302 for AATD Phase 1 trial initiation on track for H1 2024 pending CTA acceptance; BEAM-301 IND submission H1 2024.","R&D expenses rose to $140.1M Q4 (vs $86.3M) and $437.4M FY (vs $311.6M); G&A expenses $43.3M Q4 (vs $22.7M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":377709000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247334,"accession_number":"0000950170-24-002673","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Beam dosed first SCD patient, submitted CTA for AATD, cash $1.2B into 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in BEACON Phase 1/2 trial of BEAM-101 for sickle cell disease; initial data expected H2 2024.","CTA submitted for BEAM-302 in alpha-1 antitrypsin deficiency; trial initiation planned H1 2024.","IND for BEAM-301 in glycogen storage disease 1a on track for H1 2024.","Estimated cash, cash equivalents and marketable securities of $1.2B as of Dec 31, 2023, funding operations into 2027.","BEAM-201 CAR-T trial enrollment ongoing; initial clinical dataset expected H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264796,"accession_number":"0001193125-23-295457","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Beam Therapeutics appoints Christi Shaw, former Kite CEO, to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 7 to 8 members; Shaw appointed as Class III director with term until 2026.","Shaw brings over 30 years biopharma experience, most recently CEO of Kite (Gilead) until March 2023.","Previously held senior roles at Lilly, Novartis, and Johnson & Johnson; currently on Avantor board.","Shaw will receive compensation per company's non-employee director policy dated March 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264795,"accession_number":"0000950170-23-060660","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Q3 2023: net loss $96.1M, Lilly deal up to $600M, pipeline on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $96.1M ($1.22 per share) vs $109.6M ($1.56) in Q3 2022; R&D $100M, G&A $25.4M.","Cash and securities $1.0B as of Sep 30, 2023; expected runway into H2 2026 with Lilly proceeds.","Lilly acquired opt-in rights to Verve's CV programs for $200M upfront + $50M equity + up to $350M milestones ($600M total).","BEAM-101 first patient treatment by year-end 2023; initial data on multiple patients in 2024.","BEAM-302 regulatory filing in Q1 2024; BEAM-301 IND in H1 2024; BEAM-201 initial data in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":61517000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264794,"accession_number":"0000950170-23-056542","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["2.01","3.02","8.01","9.01"],"status":"ready","headline":"Beam sells opt-in rights on Verve CVD programs to Lilly for $200M + $50M equity; up to $600M total","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Beam receives $200M upfront and $50M equity (2,004,811 shares at $24.94, 15% premium to 30-day VWAP).","Eligible for up to $350M in milestone payments; total potential deal consideration up to $600M.","Deal expected to extend Beam's cash runway to second half of 2026.","Lilly acquires opt-in rights to co-develop/co-commercialize Verve's PCSK9, ANGPTL3, and undisclosed liver target programs.","Lilly agreed to 9-month lock-up on shares issued; transaction closed on October 27, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264793,"accession_number":"0001193125-23-258963","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2023-10-19T23:59:59+00:00","items":["2.05","7.01","8.01","9.01"],"status":"ready","headline":"Beam cuts ~20% workforce (100 roles), focuses on sickle cell, AATD, extends cash runway into 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduces headcount by ~100 employees (20%), expects $6.6M in Q4 2023 severance costs.","Prioritizes BEAM-101, ESCAPE, and in vivo sickle cell programs; BEAM-302 for AATD.","Explores partnerships for BEAM-201 and other CAR-T programs; pauses hepatitis B program.","Cash, equivalents, and securities of $1.1B (June 30, 2023) expected to fund operations into 2026.","Strategic restructuring aims to streamline operations and focus on near-term value drivers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281999,"accession_number":"0000950170-23-039356","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Q2 net loss $82.8M; BEAM-101/201 trials advance, in vivo programs accelerated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $82.8M ($1.08/shr) vs $72.0M ($1.02/shr) in Q2 2022; R&D spend $97.6M (up 31% YoY).","Cash $1.1B unchanged from year-end 2022; runway extends at least into 2025.","BEACON trial: consented patients sufficient to fill sentinel and initiate expansion; initial data expected 2024.","BEAM-201: first patient consented, dosing expected Q3 2023; multiple clinical sites open.","BEAM-302 accelerated to first in vivo liver regulatory filing in Q1 2024; BEAM-301 filing in H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":44324000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301043,"accession_number":"0000950170-23-027026","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Beam Therapeutics shareholders reelect two directors, ratify auditor, approve say-on-pay at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["John Evans elected with 48.7M for, 250k against; John Maraganore with 41.6M for, 7.4M against.","Ratification of Deloitte & Touche as auditor passed with 60.1M for, 32k against.","Advisory vote on executive compensation approved with 47.0M for, 2.0M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301042,"accession_number":"0001193125-23-140832","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Beam Therapeutics increases ATM equity offering capacity by $300M to $1.1B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Added $300M in capacity to existing $800M at-the-market equity offering with Jefferies.","As of May 10, 2023, ~$772.8M had been sold; remaining capacity increases to ~$327.2M.","Terms unchanged; shares sold via ATM method on Nasdaq under existing shelf registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301041,"accession_number":"0000950170-23-020063","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Q1 net loss $96.5M ($1.33/sh); BEACON trial advancing, BEAM-201 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $96.5M ($1.33/sh) vs $69.2M ($1.01/sh) YoY; R&D spend up to $99.6M.","Cash, equivalents and securities $1.1B; runway expected at least into 2025.","BEACON trial sentinel cohort: first patient withdrawn (non-medical), 2 enrolled; full cohort expected in 2023.","BEAM-201 Phase 1/2 for T-ALL/T-LL on track to dose first patient by mid-2023.","Gopi Shanker appointed CSO; regulatory filings for BEAM-301 (late 2023/early 2024) and BEAM-302 (early 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":24208000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320931,"accession_number":"0000950170-23-004858","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Therapeutics reports Q4 2022 net loss of $38.3M; cash at $1.1B, runway into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2022: $38.3M ($0.54/share) vs $64.7M ($0.95/share) in Q4 2021; full year net loss $289.1M ($4.13/share).","Cash, cash equivalents and marketable securities $1.1B as of Dec 31, 2022, up from $965.6M at Dec 31, 2021.","R&D expenses $86.3M in Q4 2022, down from $96.8M in Q4 2021; G&A expenses $22.7M vs $17.8M.","Pipeline milestones: BEAM-101 sentinel cohort enrollment to finish 2023, BEAM-201 first patient dosing by mid-2023, BEAM-301 and BEAM-302 regulatory filings in late 2023/early 2024.","North Carolina manufacturing facility expected to commence cGMP operations in late 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":60920000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320930,"accession_number":"0001193125-23-004131","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Beam Therapeutics reports pipeline progress, ~$1B cash, and outlines milestones for 2023-2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Estimated $1.0B cash, cash equivalents, and marketable securities as of Dec 31, 2022; cash runway expected into 2025.","BEAM-101 (SCD): BEACON trial sentinel cohort enrollment completion and expansion cohort initiation expected in 2023; data from multiple patients in 2024.","BEAM-201 (T-ALL/T-LL): FDA IND clearance; first patient dosing expected by mid-2023 in Phase 1/2 trial.","BEAM-301 (GSDIa) regulatory submission planned by late 2023/early 2024; BEAM-302 (AATD) submission planned early 2024.","North Carolina manufacturing facility expected to initiate GMP operations in late 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339051,"accession_number":"0000950170-22-022313","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Therapeutics Q3 net loss $109.6M; BEACON trial enrollment started for BEAM-101","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $109.6M ($1.56/sh) vs $28.1M ($0.42/sh) in Q3 2021; R&D spend $85.3M.","Cash, cash equivalents and marketable securities $1.1B as of Sep 30, 2022, up from $965.6M.","Patient recruitment underway in BEACON trial for BEAM-101; first sickle cell patient enrollment expected by year-end 2022.","BEAM-302 nominated as development candidate for alpha-1 antitrypsin deficiency; targeting in vivo DNA correction of E342K mutation.","BEAM-201 IND response submitted to FDA after clinical hold; no BEAM-102 IND filing in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":40883000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356419,"accession_number":"0000950170-22-018147","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2022-09-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Beam Therapeutics enters license collaboration with Orbital; will consolidate it financially","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Beam receives 75M shares of Orbital common stock; expects to consolidate Orbital under ASC 810.","Cross-licenses for non-viral delivery and RNA design; exclusive fields for each party run three years.","Beam's Giuseppe Ciaramella becomes Orbital interim CEO; other Beam executives take interim leadership roles.","Three Beam directors (Burow, Evans, Maraganore) join Orbital board; ARCH Venture Partners holds Orbital stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356418,"accession_number":"0000950170-22-017868","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2022-08-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Beam announces FDA formal clinical hold letter for BEAM-201 IND; plans Q4 2022 response","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA placed BEAM-201 IND on clinical hold for relapsed/refractory T-ALL/T-LBL.","Letter dated Aug 25 requests additional control data and off-target editing analyses.","Requests also include additional cytokine assay data and updated investigator brochure.","Beam intends to complete studies and submit Complete Response in Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356417,"accession_number":"0000950170-22-015736","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Q2 net loss $72M; BEAM-201 IND on clinical hold; cash $1.2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $72.0M ($1.02/share) vs $76.3M ($1.23) prior year; R&D spend $74.6M (+64% YoY).","BEAM-201 IND placed on clinical hold by FDA July 29; awaiting official letter.","Patient enrollment in BEACON Phase 1/2 for BEAM-101 on track for 2H 2022.","John Lo, Ph.D., appointed Chief Commercial Officer; Amended Verve deal adds CV target.","Cash, cash equivalents and marketable securities $1.2B as of June 30, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":25084000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356416,"accession_number":"0000950170-22-013559","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2022-08-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA places clinical hold on Beam's BEAM-201 IND for T-ALL/T-LL","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA clinical hold on BEAM-201 IND for relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma.","Beam informed via FDA email on July 29, 2022; IND submitted end of June.","BEAM-201 is an anti-CD7, multiplex-edited allogeneic CAR-T candidate.","FDA to provide official clinical hold letter within 30 days; Beam plans updates after discussions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374837,"accession_number":"0000950170-22-011501","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Beam Therapeutics shareholders elect three Class II directors, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three director nominees (Fishman, Ho, Walsh) elected with ~39.5M votes each.","Deloitte & Touche ratified as auditor for FY2022 with 51.8M for, 3.1M against.","Advisory vote on executive compensation approved with 36.9M for, 5.7M against.","Shareholders selected every year as the frequency of say-on-pay votes; board adopts annual policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":374836,"accession_number":"0000950170-22-008231","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2022-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam Therapeutics Q1 net loss $69.2M; cash $1.2B; pipeline on track for H2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $69.2M ($1.01 per share) vs $201.6M ($3.35) in Q1 2021 due to prior-year in-process R&D charge.","Cash, equivalents and marketable securities $1.2B as of March 31, 2022 (vs $965.6M at Dec 31, 2021).","R&D expenses $65.4M (excl. $155M Guide Therapeutics acquisition cost in Q1 2021); G&A $19.2M.","BEAM-101 enrollment, BEAM-102 IND, and BEAM-201 IND all on track for second half of 2022.","Initiated AUNT natural history study in sickle cell trait; appointed Manmohan Singh to exec leadership and Anne Marie Woodland as head of regulatory."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":8432000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393264,"accession_number":"0000950170-22-002162","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2022-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Beam reports $1.2B cash post-Pfizer deal; H2 2022 IND milestones set for SCD programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Pfizer collaboration: $300M upfront, up to $1.35B milestones for in vivo base editing programs.","Cash $1.2B including Pfizer payment; Q4 net loss $64.7M ($0.95/shr), FY net loss $370.6M ($5.77/shr).","Planned H2 2022 IND submissions: BEAM-101 (SCD Phase 1/2), BEAM-102 (SCD), BEAM-201 (T-ALL/TLL).","IND-enabling studies for BEAM-301 (liver-targeted GSDIa) in 2022; second CAR-T candidate nomination due.","R&D expenses $96.8M Q4 (up from $32.5M), G&A $17.8M Q4 (up from $8.4M) YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":51844000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393263,"accession_number":"0000950170-22-000163","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Beam Therapeutics enters $1.35B collaboration with Pfizer for in vivo base editing programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive 4-year collaboration with Pfizer on 3 rare disease targets (liver, muscle, CNS).","$300M upfront; eligible for up to $1.35B milestones plus royalties.","Preliminary cash: ~$0.9B actual, $1.2B pro forma including $300M upfront.","First subject enrollment in BEAM-101 Phase 1/2 trial for sickle cell disease expected H2 2022.","BEAM-301 (GSDIa) named fourth dev candidate; IND-enabling studies planned in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":411768,"accession_number":"0000950170-21-003291","cik":1745999,"company_name":"Beam Therapeutics Inc.","ticker":"BEAM","form_type":"8-K","filed_at":"2021-11-08T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Beam gets FDA clearance for first base editing IND (BEAM-101); Q3 net loss $28.1M, cash $933.4M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA cleared IND for BEAM-101 (sickle cell disease); first open IND for base editing.","Beam initiated IND-enabling studies for BEAM-102 (Makassar base editing for sickle cell).","Q3 net loss $28.1M ($0.42/share); R&D $54.6M, G&A $15.8M.","Cash, equivalents & securities $933.4M as of Sep 30, 2021, up from $299.7M at Dec 31, 2020.","Non-exclusive license to Sana for Cas12b for $50M upfront; potential milestones/royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3349232664.2975855,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-08T23:59:59+00:00|411768"}